Oxford and London researchers discover potential AML treatment by targeting enzymes responsible for cell response to oxygen.
Scientists at the University of Oxford and the Institute of Cancer Research in London have discovered a potential treatment strategy for Acute Myeloid Leukaemia (AML) by targeting enzymes responsible for the body's cells' response to oxygen levels. Their study, published in Nature Cancer, reveals that blocking these enzymes can significantly halt AML in mice and patient samples without affecting normal blood cell production. The researchers are now looking to translate their findings into clinical trials for leukaemia treatment.
April 18, 2024
13 Articles